Asthma – Supportive Cannabis Treatment Research Project – Self-treatment
Cannabis treatment is certified by about 80% of asthma patients and patients with other allergic diseases. Treatment is carried out in three ways: external application – cannabis embrocations, internal application – using cannabis oil, and inhaling cannabis or evaporated resin. Resin of frankincense oil or cannabis oil evaporations can be used as an adjunct.
It is recommended to embrocate cannabis embrocation into the chest and neck in case of early acute respiratory stress with the first signs of tightness in the airways.
If the embrocation does not bring relief and a patient feels an attack coming on, it is effective to inhale the smoke from the bong, or vapor from the evaporator. After that the bronchodilator effect of cannabis comes, which prevents seizures progression and a patient will soon feel as usual.
One teaspoon of cannabis oil added to a warm drink or spread on a piece of bread at night is a very good asthma long-time care.
After the first month of cannabis treatment in accord with a physician, the consumption of customary drugs, especially steroids, which are generally hard on patients, can be reduced. Sometimes, after a long-term treatment (1-2 years), you can not only reduce asthma symptoms, but also reduce the body\’s sensitivity to allergens.
For patients who have problems with fats consumption cannabis oil can be replaced by cannabis powder, which is used in the case of glaucoma or Parkinson\’s disease treatment.
Inhaling cannabis from the evaporator the steam must act broncholyticly and improve breathing. The advantage is the rapid, almost immediate effect. It is practically proven that asthmatics are better inhale 5% THC cannabis than the strong strains, which can cause irritation and coughing, and can also produce the opposite effect, causing bronchospasms.
There are scientific reasons for cannabis treatment of asthma, for example, some of them are represented in the study \”Health Aspects of Cannabis – Asthma bronchiale\”.
Studying marijuana effects on the respiratory system researchers discovered broncholytic effect with healthy volunteers. The volunteers inhaled marijuana smoke with 85 or 32 mg of THC per kilogram of body weight. The group that received the higher doses of THC had a 38% reduction of resistance, and airway conductance increase equaled to 44%. The group that received lower doses of THC had lower, but still significant changes in the normal state. The sensitivity of the respiratory center to CO2 levels was not altered by the consumption of any doses, so central respiratory depression was not documented.
Methacholine vapors inhalation and physical exercises were used in another study of asthma patients. They were given a placebo, physiological saline solution, isoproterenol and marijuana vapors containing one gram of THC. Marijuana vapors and isoproterenol effectively neutralized both an asthma attack caused by methacholine and by physical exercises, whereas placebo had no effect.
Placebo-ethanol, 200 mcg of THC in ethanol and solbutamole (100 mg), was tested in another study with a group of 10 patients with stable asthmatic syndrome. The research was focused mainly on the measurement of a second lung capacity, FEV and Peak Flow Rate. THC and solbutamol significantly improved lung functioning. Solbutamole caused more rapid improvement, but effects of these two medications were over in an hour after application.
Delta-8 and Delta-9-tetrahydrocannabinol have broncholytic effect, although neither cannabinol, nor cannabidiol do not have this effect. It follows that only psychoactive component of marijuana is able to produce the desired effect. Within 20 days of the study no THC addiction was documented. Asthma treatment is a chronic action, and therefore it is necessary to carry out studies on the impact nonresponsiveness.
THC aerosol is the most suitable dosage form for asthma treatment. However, doses which cause mental effects are unclear. The mechanism by which THC increases airway conductance is distinguished from the normal beta-adrenergic stimulants. It can be an advantage in the development of resistance after repeated use of beta-adrenergic stimulants, which occurs in many asthma patients.